

Notice of Allowability

Application No.

10/693,327

Applicant(s)

ARMOUR ET AL.

Examiner

Art Unit

Robert Shiao

1626

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to responses filed on 11/23/2005.
2. ☒ The allowed claim(s) is/are 1-2, 5, 10-12, 14-15, and 18, now are 1-9.
3. ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some* c) ☐ None of the:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
- (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
- 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
- (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|---|--|
| 1. <input type="checkbox"/> Notice of References Cited (PTO-892) | 5. <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 2. <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 6. <input checked="" type="checkbox"/> Interview Summary (PTO-413),
Paper No./Mail Date _____ |
| 3. <input type="checkbox"/> Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____ | 7. <input checked="" type="checkbox"/> Examiner's Amendment/Comment |
| 4. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit
of Biological Material | 8. <input checked="" type="checkbox"/> Examiner's Statement of Reasons for Allowance |
| | 9. <input type="checkbox"/> Other _____ |

DETAILED ACTION

1. This application claims benefit of the foreign application:

UNITED KINGDOM 0224919.1 with a filing date 10/25/2002.

2. Amendment of claims 1, 10-12, 14-15, and 18, and cancellation of claims 3-4, 6-9, 13, 16-17, and 19-21 in the amendment filed on November 23, 2005, is acknowledged. Claims 1-2, 5, 10-12, 14-15, and 18 are pending in the application.

Responses to Amendment

3. Since the non-elected subject matter, i.e., heteroaryl, heterocycle, het², het³, het⁴, etc, has been eliminated, therefore, objection of claims 1-2, 5, 10-12, and 18 has been withdrawn. Since claims 3-4, 6-9, 13, and 16-17 have been cancelled, therefore, objection of claims 3-4, 6-9, 13, and 16-17, is obviated herein.

EXAMINER'S AMENDMENT

4. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee. Authorization for this examiner's amendment was given in a telephone interview with Carl J. Goddard on January 23, 2006. The application has been amended as follows:

Art Unit: 1626

In claim 14, lines 1-17, after "treatment of aggression," delete "Alzheimer's disease, anorexia nervosa, anxiety disorder, asthma, atherosclerosis, cardiac failure, cardiovascular disease, cataract, central nervous system disease, cerebrovascular ischemia, cirrhosis, cognitive disorder, Cushing's disease, depression, diabetes mellitus, dysmenorrhoea, edema, emesis, endometriosis, gastrointestinal disease, glaucoma, gynaecological disease, heart disease, hypertension, hyponatremia, intrauterine growth retardation, ischemia, ischemic heart disease, lung tumor, micturition disorder, mittelschmerz, motion sickness, neoplasm, nephrotoxicity, non-insulin dependent diabetes, obesity, obsessive/compulsive disorder, ocular hypertension, premature ejaculation, premature labor, pulmonary disease, Raynaud's disease, renal disease, renal failure, male and female sexual dysfunction, sleep disorder, spinal cord injury, thrombosis, urogenital tract infection, urolithiasis," and **insert** -- anorexia nervosa, anxiety, depression, or dysmenorrhoea,--

In claim 15, line 2, after "or anxiety", delete "disorder"

In claim 18, page 13, line 3, after "carrier", delete ":", and insert

--.

Reasons for Allowance

5. The following is an examiner's statement of reasons for allowance:

Claims 1-2, 5, 10-12, and 18 are directed to an allowable product. Pursuant to the procedures set forth in the Official Gazette notice dated March 26, 1996 (1184 O.G. 86), claims 14 and 15, directed to the process of making or using the patentable product, previously withdrawn from consideration as a result of a restriction requirement, are now subject to being rejoined. Claims 14 and 15 are hereby rejoined and fully examined for patentability under 37 CFR 1.104.

Since all claims previously withdrawn from consideration under 37 CFR 1.142 have been rejoined, the restriction requirement made in the Office action mailed on August 05, 2005, is hereby withdrawn.


Claims 1-2, 5, 10-12, 14-15, and 18 are neither anticipated nor rendered obvious over the art of record, and therefore are allowable. This invention relates to triazole compounds useful in therapy. The closest reference is Alanine et al. US 6,265,426, discloses triazole derivatives. The difference between Alanine et al. and instant claims is that the instant compounds of formula (I) have not been found. Suggestion for modification of above record to obtain the instant claimed compounds/compositions and methods of use, has not been found. Claims 1-2, 5, 10-12, 14-15, and 18 are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."


Conclusions

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert Shiao whose telephone number is (571) 272-0707. The examiner can normally be reached on 8:30 AM - 5:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph K. McKane can be reached on (571) 272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Joseph K. McKane
Supervisory Patent Examiner
Art Unit 1626



Robert Shiao, Ph.D.
Patent Examiner
Art Unit 1626

January 24, 2006